Use of <font color="red">hormonal_2</font> <font color="red">contraceptives_2</font> and risk of HIV-1 transmission : a prospective cohort study . 
<br>
<br> BACKGROUND <font color="red">Hormonal_2</font> <font color="red">contraceptives_2</font> are used widely but their effects on HIV-1 risk are unclear . We aimed to assess the association between <font color="red">hormonal_2</font> <font color="red">contraceptive_2</font> use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners . 
<br> METHODS In this prospective study , we followed up 3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries . Among injectable and oral <font color="red">hormonal_2</font> <font color="red">contraceptive_2</font> users and <font color="red">non_1</font> <font color="red">-_1</font> <font color="red">users_1</font> <font color="red">,_1</font> we compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men . The primary outcome measure was HIV-1 seroconversion . We used Cox proportional hazards regression and marginal structural modelling to assess the effect of <font color="red">contraceptive_1</font> <font color="red">use_1</font> on HIV-1 risk . 
<br> FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was female ( median follow - up 18·0 [ IQR 12·6 - 24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person - years in <font color="red">women_1</font> <font color="red">who_1</font> <font color="red">used_1</font> <font color="red">hormonal_2</font> <font color="red">contraception_2</font> and 3·78 per 100 person - years in <font color="red">those_1</font> <font color="red">who_1</font> <font color="red">did_1</font> <font color="red">not_1</font> ( adjusted hazard ratio 1·98 , 95% CI 1·06 - 3·68 , p=0·03 ) . Among 2476 couples in which the HIV-1-seronegative partner was male ( median follow - up 18·7 [ IQR 12·8 - 24·2 ] months ) , rates of HIV-1 transmission from women to men were 2·61 per 100 person - years in couples in which <font color="red">women_1</font> <font color="red">used_1</font> <font color="red">hormonal_2</font> <font color="red">contraception_2</font> and 1·51 per 100 person - years in couples in which <font color="red">women_1</font> <font color="red">did_1</font> <font color="red">not_1</font> <font color="red">use_1</font> <font color="red">hormonal_2</font> <font color="red">contraception_2</font> ( adjusted hazard ratio 1·97 , 95% CI 1·12 - 3·45 , p=0·02 ) . Marginal structural model analyses generated much the same results to the Cox proportional hazards regression . 
<br> INTERPRETATION Women should be counselled about potentially increased risk of HIV-1 acquisition and transmission with <font color="red">hormonal_1</font> <font color="red">contraception_1</font> <font color="red">,_1</font> especially injectable methods , and about the importance of dual protection with condoms to decrease HIV-1 risk . <font color="red">Non_1</font> <font color="red">-_1</font> <font color="red">hormonal_1</font> <font color="red">or_1</font> <font color="red">low_1</font> <font color="red">-_1</font> <font color="red">dose_1</font> <font color="red">hormonal_1</font> <font color="red">contraceptive_1</font> <font color="red">methods_1</font> should be considered for women with or at - risk for HIV-1 . 
<br> FUNDING US National Institutes of Health and the Bill & Melinda Gates Foundation .